Straumann Holding AG (OTCMKTS:SAUHY – Get Free Report) saw a large decline in short interest during the month of August. As of August 14th, there was short interest totaling 1,001 shares, a decline of 80.6% from the July 30th total of 5,152 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily volume of 47,320 shares, the days-to-cover ratio is currently 0.0 days.
Straumann Stock Performance
OTCMKTS:SAUHY opened at $11.38 on Friday. The stock’s 50-day moving average is $12.52 and its 200-day moving average is $11.68. Straumann has a 1-year low of $9.44 and a 1-year high of $13.61.
Analyst Ratings Changes
SAUHY has been the subject of a number of research analyst reports. Morgan Stanley reiterated an “underweight” rating on shares of Straumann in a research report on Tuesday, June 30th. Citigroup restated a “sell” rating on shares of Straumann in a research report on Thursday, July 9th. BMO Capital Markets started coverage on shares of Straumann in a research note on Wednesday, July 8th. They set an “outperform” rating on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of Straumann from a “buy” rating to a “hold” rating in a report on Friday, August 21st. Finally, Barclays reiterated an “overweight” rating on shares of Straumann in a research note on Thursday, June 18th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.
Straumann Company Profile
Straumann (OTCMKTS:SAUHY) is a Swiss-based dental technology company that develops, manufactures and markets restorative, regenerative and digital solutions for dental professionals. The company’s core offerings center on implant-supported restorations and components, biomaterials used for bone and soft-tissue regeneration, and a range of prosthetic products used by dentists and dental laboratories to restore oral function and aesthetics.
In addition to implant and biomaterial product lines, Straumann provides digital dentistry solutions that support treatment planning and workflows.
Featured Stories
- Five stocks we like better than Straumann
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Straumann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Straumann and related companies with MarketBeat.com's FREE daily email newsletter.
